Abstract
Drug-resistant Mycobacterium tuberculosis among new tuberculosis patients, Yangon, Myanmar.
Highlights
All new case-patients in national TB program clinics are routinely treated with isoniazid, rifampicin, ethambutol, and pyrazinamide without drug susceptibility testing of Mycobacterium tuberculosis
We report on the pattern of drug resistance to first-line anti-TB drugs among M. tuberculosis complex isolates from Zone 1 TB center in Yangon, which receives approximately 70% of the national TB programs’ TB cases in Yangon
The World Health Organization/ International Union Against Tuberculosis and Lung Diseases global survey in the year 2000 (6) showed that the prevalence of resistance to at least one anti-TB drug among new cases ranged from 1.7% to 36.9%
Summary
Drug-Resistant Mycobacterium tuberculosis among New Tuberculosis Patients, Yangon, Myanmar The World Health Organization/International Union Against Tuberculosis and Lung Diseases urges all national TB programs to practice the Directly Observed Treatment-Short Course (DOTS) strategy as well as to closely monitor the patterns and trends of anti-TB drug resistance (2). All new case-patients in national TB program clinics are routinely treated with isoniazid, rifampicin, ethambutol, and pyrazinamide without drug susceptibility testing of Mycobacterium tuberculosis.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
